May 22 2012
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment. The AUA's evidence-based guidelines are intended to promote the highest standards of clinical care. Uroplasty's Urgent® PC Neuromodulation System is the only FDA cleared device that delivers PTNS.
"It is noteworthy that the world's most prestigious urology society has recognized the clinical significance of PTNS in their OAB treatment guidelines," said David Kaysen, President and CEO of Uroplasty. "We will present these guidelines to the medical directors of U.S. private payers and Medicare carriers as we continue our efforts to expand coverage for our Urgent PC Neuromodulation System."